Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer

Cancer

Volumn 116, Issue 24, 2010, Pages 5650-5658

  Zilli, Thomas ^a   Chagnon, Miguel ^b   Van Nguyen, Thu ^a   Bahary, Jean Paul ^a   Guay, Jean Pierre ^a   Dufresne, Alix ^a   Taussky, Daniel ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

abdominal fat; body mass index; obesity; prostate cancer; radiotherapy

Indexed keywords

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BODY MASS; CANCER RADIOTHERAPY; CANCER RISK; COMORBIDITY; FOLLOW UP; GLEASON SCORE; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SECOND CANCER; SUBCUTANEOUS FAT; TUMOR CLASSIFICATION; WAIST CIRCUMFERENCE;

ABDOMINAL FAT; AGED; BODY MASS INDEX; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OBESITY; PROSTATIC NEOPLASMS; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

EID: 78650127823     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25539     Document Type: Article

References (51)

1. Carroll KK,. Obesity as a risk factor for certain types of cancer. Lipids. 1998; 33: 1055-1059.
2. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003; 95: 1240-1244.
3. Porter MP, Stanford JL,. Obesity and the risk of prostate cancer. Prostate. 2005; 62: 316-321.
4. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22: 439-445.
5. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005; 174: 919-922.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638.
7. Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV,. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer. 2007; 109: 1493-1498.
8. Palma D, Pickles T, Tyldesley S,. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int. 2007; 100: 315-319.
9. Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006; 107: 631-639.
10. Stroup SP, Cullen J, Auge BK, L'Esperance JO, Kang SK,. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer. 2007; 110: 1003-1009.
11. Freedland SJ, Aronson WJ,. Obesity and prostate cancer. Urology. 2005; 65: 433-439.
12. Gunnell D, Oliver SE, Peters TJ, et al. Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer. 2003; 88: 1682-1686.
13. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001; 47: 52-58.
14. Loeb S, Yu X, Nadler RB, et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol. 2007; 177: 102-106; discussion 106.
15. Mallah KN, DiBlasio CJ, Rhee AC, Scardino PT, Kattan MW,. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer. 2005; 103: 2030-2034.
16. Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL,. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 71: 1302-1308.
17. Merrick GS, Butler WM, Wallner KE, et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology. 2005; 65: 95-100.
18. Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Adamovich E,. Obesity is not predictive of overall survival following permanent prostate brachytherapy. Am J Clin Oncol. 2007; 30: 588-596.
19. Jayachandran J, Aronson WJ, Terris MK, et al. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2008; 102: 964-968.
20. Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M III,. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 59: 6-10.
21. Wong JR, Gao Z, Merrick S, et al. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int J Radiat Oncol Biol Phys. 2009; 75: 49-55.
22. Schoen RE, Thaete FL, Sankey SS, Weissfeld JL, Kuller LH,. Sagittal diameter in comparison with single slice CT as a predictor of total visceral adipose tissue volume. Int J Obes Relat Metab Disord. 1998; 22: 338-342.
23. Baumgartner RN, Heymsfield SB, Roche AF, Bernardino M,. Abdominal composition quantified by computed tomography. Am J Clin Nutr. 1988; 48: 936-945.
24. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE,. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr. 1982; 36: 172-177.
25. von Hafe P, Pina F, Perez A, Tavares M, Barros H,. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res. 2004; 12: 1930-1935.
26. Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB,. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol. 1990; 131: 794-803.
27. Moon HG, Ju YT, Jeong CY, et al. Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol. 2008; 15: 1918-1922.
28. Oh TH, Byeon JS, Myung SJ, et al. Visceral obesity as a risk factor for colorectal neoplasm. J Gastroenterol Hepatol. 2008; 23: 411-417.
29. Schapira DV, Kumar NB, Lyman GH, Cavanagh D, Roberts WS, LaPolla J,. Upper-body fat distribution and endometrial cancer risk. JAMA. 1991; 266: 1808-1811.
30. Scardino P,. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2005; 3 (suppl 1): S29-S33.
31. Bittner N, Merrick GS, Stewart R, et al. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. Urol Oncol. 2009.
32. Freedland SJ, Terris MK, Platz EA, Presti JC Jr,. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology. 2005; 66: 108-113.
33. Gallina A, Karakiewicz PI, Hutterer GC, et al. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer. 2007; 121: 791-795.
34. Pruthi RS, Swords K, Schultz H, Carson CC III, Wallen EM,. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. J Urol. 2009; 181: 574-577; discussion 578.
35. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW,. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009; 12: 259-263.
36. Isbarn H, Jeldres C, Budaus L, et al. Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series. Urology. 2009; 73: 615-619.
37. Wallstrom P, Bjartell A, Gullberg B, Olsson H, Wirfalt E,. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer. 2009; 100: 1799-1805.
38. Pischon T, Boeing H, Weikert S, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3252-3261.
39. Culig Z,. New insights into the role of interleukin-6 in human prostate cancer. J Urol. 2009; 182: 1255-1256.
40. De Marzo AM, Platz EA, Epstein JI, et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006; 30: 1281-1291.
41. van Roermund JG, Witjes JA,. The impact of obesity on prostate cancer. World J Urol. 2007; 25: 491-497.
42. Seidell JC, Visscher TL,. Body weight and weight change and their health implications for the elderly. Eur J Clin Nutr. 2000; 54 (suppl 3): S33-S39.
43. Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005; 11: 6889-6894.
44. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
45. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 1013-1021.
46. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 102: 39-46.
47. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-4456.
48. Smith MR, Bae K, Efstathiou JA, et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008; 26: 4333-4339.
49. Brenner DJ, Curtis RE, Hall EJ, Ron E,. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000; 88: 398-406.
50. Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD,. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys. 2006; 66: 669-673.
51. Neugut AI, Ahsan H, Robinson E, Ennis RD,. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer. 1997; 79: 1600-1604.